



Dave Handler experienced great success in cardiology marketing and sales for GE Healthcare. Now, he leads Corindus to secure *vascular robotics* in the cath lab.

***“This is the break-out year for Corindus,” says Handler.***

#### VASCULAR ROBOTICS—NEXT ‘BIG THING’ IN THE CATH LAB?

Currently, percutaneous coronary intervention (PCI) procedures are performed in a cath lab via x-ray angiography imaging, which exposes physicians to significant occupational hazards—including (1) radiation exposure, (2) chronic orthopedic ailments, and (3) fatigue due to the required use of heavy lead-protection garments. For the first time in a cath lab, the CorPath™ system is designed to significantly reduce radiation exposure, fatigue, and other occupational hazards by allowing physicians to operate in an ergonomically correct position while protected from radiation exposure. **Precise device manipulation is a key challenge in PCI procedures today.** Via CorPath’s stability and precision controlled movements, the system empowers interventional cardiologists to improve their accuracy and potentially improve clinical outcomes in PCI procedures. Currently, these procedures are done manually and rely on the restricted precision and accuracy of a physician’s hands while standing bedside in a hazardous and stressful environment. **“Robotics will aid in the teaching, standardization, and implementation of how catheter-based therapies are delivered to patients—for treatment of vascular disease from the head to the feet,”** says Dr. Peter J. Fitzgerald, Director, Center for Cardiovascular Technology, Stanford University Medical Center.

#### COMPANY EXPECTS TO COMMERCIALIZE ITS FIRST CLINICAL APPLICATION FOR CORPATH™—‘PCI’—THIS YEAR.

“The big focus in today’s healthcare environment is **improving quality**. I want physicians to see CorPath as the **greatest breakthrough tool that they’ve been given since they started in the interventional cath lab,**” says Handler. “They’ve been given tremendous new devices to use with their patients—new stents, new guidewires, new balloons, new imaging equipment. But they haven’t been given any new tools to help them bring the entire procedure together in an integrated way that allows them to go to an entirely new level of quality outcomes for patients *and* to do so in a more safe, ergonomic way for themselves,” Handler says. **“Within five years I believe CorPath has the potential to be globally ubiquitous in PCI procedures.** We expect CorPath will be seen as the new standard of care, the new way that you perform PCI procedures. In addition, we will be well on our way in starting to penetrate the next level of more advanced applications for CorPath—**structural heart repair**, for example, such as **percutaneous heart valve replacement**—applications that require a tremendous amount of precision and accuracy,” adds Handler. **“PCI is really our entry point for vascular robotics.** But it has the potential to be more than two million procedures a year globally, the potential to be well-penetrated and used every day all over the world. Not bad for the *initial* application of our CorPath platform.”



## David M. Handler

Former GE Healthcare senior executive

*Before joining Corindus Vascular Robotics on October 1, 2008, David Handler spent more than 20 years at General Electric Company (NYSE: GE). In 2001, Mr. Handler was selected to lead marketing and sales for GE Healthcare’s newly formed Interventional Cardiology business unit, including the cath lab imaging, monitoring and IT businesses. Most recently he served as General Manager for the Global MRI marketing department immediately before joining Corindus. Prior to that, he held a variety of sales, marketing and product management leadership positions at GE. Mr. Handler earned a bachelor of arts degree in economics from Union College, Schenectady, N.Y., and has extensive management training from GE’s “Jack Welch Leadership Development Center” in Crotonville, N.Y.*